AstraZeneca in $1.15B Deal for Pearl Therapeutics
June 10 (Bloomberg) -- Bloomberg's Anna Edwards reports that AstraZeneca has agreed to a $1.15 billion deal to buy Pearl Therapeutics, a maker of therapies for respiratory disease. She speaks on Bloomberg Television's "Countdown."
Most Recent Videos
Soylent: The Food of the Future?
01:03 - Rob Rhinehart, Soylent's chief executive officer, discusses the company's quest to disrupt the food industry. He speaks with Bloomberg's Emily Chang on "Bloomberg West." (Source: Bloomberg)